Amoxicillin + Omeprazole + Rifabutin

Helicobacter Pylori Infection

Helicobacter Pylori Infection Administer 4 capsules PO with food q8hr for 14 days Each dose (4 capsules) include 1000 mg amoxicillin, 40 mg omeprazole, and 50 mg rifabutin

Severe renal impairment (GFR <30 mL/min): Avoid use

Hepatic impairment: (Child-Pugh Class A, B, or C): Avoid use

Take with food Swallow capsules whole with a full glass of water (8 ounces); do not crush or chew capsules Do not take with alcohol

Known hypersensitivity to omeprazole, amoxicillin or any other betalactam antibacterial drugs, rifabutin or any other rifamycin, or any components or excipients Rilpivirine-containing products. Delavirdine. Voriconazole.

Hypersensitivity Reactions: Serious and occasionally fatal reactions (e.g., anaphylaxis) have been reported with components of Amoxicillin + Omeprazole + Rifabutin. If hypersensitivity reactions occur, discontinue Amoxicillin + Omeprazole + Rifabutin and institute immediate therapy (e.g., anaphylaxis management). Clostridioides difficile-Associated Diarrhea (CDAD): Evaluate if diarrhea occurs. Reduction in the Efficacy of Hormonal Contraceptives: Additional nonhormonal highly effective methods of contraception should be used while taking Amoxicillin + Omeprazole + Rifabutin. Acute Interstitial Nephritis (AIN): Observed in patients taking (Proton Pump Inhibitors (PPIs) and penicillins. Discontinue Amoxicillin + Omeprazole + Rifabutin if AIN develops. Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue Amoxicillin + Omeprazole + Rifabutin and evaluate.

Not Classi Pregnancy Based on animal reproduction studies, therapy may cause fetal harm when administered to pregnant women; there are no adequate and well controlled studies of amoxicillin, omeprazole, or rifabutin (used separately or together) in pregnant women; therapy is generally not recommended for use in pregnancy; if therapy administered during pregnancy, advise pregnant women of potential risk to fetus Rifabutin Fetal malformations not observed in rat or rabbit reproduction studies given rifabutin at dose levels up to 200 mg/kg (6 to 13 times recommended human dose); in rats, given rifabutin at 200 mg/kg/day (about 6 times recommended human daily dose), there was a decrease in fetal viability; increased skeletal anomalies were observed in rats and rabbits at 40 and 80 mg/kg/day, respectively (corresponding to approximately an equivalent dose and 5 times the recommended human daily dose); maternal toxicity was noted at 80 mg/kg in rabbits Omeprezole There are no adequate and well-controlled studies in pregnant women; available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use; reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 1.13 to 11 times an oral human dose of 120 mg Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with 23 times and 14 times, respectively, of an oral human dose of 120 mg esomeprazole or omeprazole; changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 11 times an oral human dose of 120 mg esomeprazole or omeprazole; when maternal administration was confined to gestation only, there were no effects on bone physeal morphology in offspring at any age Amoxicillin Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with amoxicillin use have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes; no adverse developmental effects were observed in animal reproduction studies with administration of amoxicillin to pregnant mice and at doses up to 3 to 6 times an oral human dose of 3 grams Contraception Drug components interact with hormonal contraceptives resulting in lower levels of these contraceptives; female patients taking hormonal contraceptives should use an additional non-hormonal highly effective method of contraception while receiving therapy Infertility Based on findings in rodents, drug may impair fertility in males of reproductive potential Lactation The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breast-fed child from drug or from the underlying condition Rifabutin There are no data on presence of drug in human milk, effects on breast-fed infant or on milk production Omeprazole There are no clinical data on effects of drug on breast-fed infant or on milk production Amoxicillin Data from a published clinical lactation study reports that drug is present in human milk; published adverse effects with amoxicillin exposure in breast-fed infant include diarrhea; There are no data on the effects of amoxicillin on milk production

Avoid concomitant use with other CYP2C19 or CYP3A4 inducers (e.g. St. John’s Wort, rifampin) as they can substantially decrease omeprazole concentrations Avoid concomitant use of with CYP2C19 and/or CYP3A4 inhibitors (e.g. fluconazole, itraconazole) as it may significantly increase plasma concentration of drug component (s) Depending on protease inhibitor, concomitant use of drug should be avoided (e.g. amprenavir, indinavir) or dose adjustments for a concomitantly administered protease inhibitor(s) may be required Concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities; avoid therapy in patients on high-dose methotrexate Concomitant use of clopidogrel and omeprazole reduces pharmacological activity of clopidogrel; avoid therapy in patients on clopidogrel; when administering drug, consider alternative anti-platelet therapy Contraindicated (27) apixaban artemether/lumefantrine cabotegravir cariprazine clarithromycin cobimetinib dienogest/estradiol valerate doravirine elbasvir/grazoprevir elvitegravir/cobicistat/emtricitabine/tenofovir DF erlotinib isavuconazonium sulfate ledipasvir/sofosbuvir lonafarnib lorlatinib lumacaftor/ivacaftor lumefantrine lurasidone mavacamten naloxegol nelfinavir ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) pacritinib panobinostat regorafenib rilpivirine roflumilast

>10% Rifabutin Discoloration of urine (30%) Neutropenia (25%) Leukopenia (17%) Rash (11%) 1-10% Omeprazole Acid regurgitation (1.9%) Upper respiratory infection (1.9%) Constipation (1.5%) Dizziness (1.5%) Rash (1.5%) Asthenia (1.3%) Back pain (1.1%) Cough (1.1%) Rifabutin Incr AST/ALT (7-9%) Thrombocytopenia (5%) Abdominal pain (4%) Diarrhea (3%) Eructation (3%) Headache (3%) Nausea/vomiting (3%) Anorexia (2%) Flatulence (2%) Anemia Myalgia Frequency Not Defined Amoxicillin Headache Rash Diarrhea, nausea, vomiting Anemia AST/ALT elevation Anaphylaxis Candidiasis (mucocutaneous), pseudomembranous colitis, serum sickness Omeprazole Fracture of bone, osteoporosis-related Hepatotoxicity (rare) Hip fracture Interstitial nephritis (rare) Pancreatitis (rare) Rhabdomyolysis Toxic epidermal necrolysis (rare) Selected adverse reactions reported ≥1% by patients receiving therapy Diarrhea Headache Nausea Abdominal pain Chromaturiac Rash Dyspepsia Vomiting Oropharyngeal pain Vulvovaginal candidiasis

Rifabutin: Elicits antibacterial effects by inhibiting DNA-dependent RNA polymerase Omeprazole: Proton pump inhibitor; binds to H+/K+-exchange ATPase (proton pump) in gastric parietal cells resulting in blocking acid secretion Amoxicillin: Ampicillin derivative; elicits antibacterial effect by inhibiting biosynthesis of cell wall mucopeptide